Companies:
49,739
Total Market Cap:
136053465432671.83
Global Rank
#379
Country Rank
#11
Market Cap
56.11 B
Price
129.05
Change (%)
1.21%
Volume
222,806
Merck KGaA's latest marketcap:
56.11 B
As of 06/26/2025, Merck KGaA's market capitalization has reached $56.11 B. According to our data, Merck KGaA is the 379th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 56.11 B |
| Revenue (ttm) | 24.93 B |
| Net Income (ttm) | 3.3 B |
| Shares Out | 434.78 M |
| EPS (ttm) | 7.57 |
| Forward PE | 12.34 |
| Ex-Dividend Date | 04/28/2025 |
| Earnings Date | 08/07/2025 |
Market Cap Chart
Data Updated: 06/26/2025
Merck KGaA's yearly market capitalization.
Merck KGaA has seen its market value grow from €34.1 B to €56.11 B since 2014, representing a total increase of 64.56% and an annual compound growth rate (CAGR) of 4.86%.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/26/2025 | €56.11 B | -21.84% | 379 |
| 12/30/2024 | €60.83 B | -2.91% | 300 |
| 12/29/2023 | €62.65 B | -20.34% | 239 |
| 12/30/2022 | €78.65 B | -20.31% | 155 |
| 12/30/2021 | €98.69 B | 61.74% | 134 |
| 12/30/2020 | €61.02 B | 33.22% | 192 |
| 12/30/2019 | €45.8 B | 17.08% | 243 |
| 12/28/2018 | €39.12 B | 0.26% | 225 |
| 12/29/2017 | €39.02 B | -9.48% | 251 |
| 12/30/2016 | €43.11 B | 10.69% | 197 |
Company Profile
About Merck KGaA
Merck KGaA is a leading science and technology company headquartered in Darmstadt, Germany. Founded in 1668, it operates globally through three key segments: Life Science, Healthcare, and Electronics.
Business Segments
-
Life Science: Provides tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers. This segment includes:
- Process development expertise and technologies (e.g., continuous bioprocessing)
- Testing kits, reagents, and services
- Environmental testing solutions for air, water, and soil
- Nutritional and quality testing products
-
Healthcare: Focuses on discovering, developing, and marketing prescription drugs and biopharmaceuticals for:
- Oncology, neurology, immunology, and fertility
- Endocrinology, cardiovascular, diabetes, and thyroid disorders
- Multiple sclerosis and general medicines
- Injection devices and disease monitoring software
-
Electronics: Supplies materials for semiconductor and display industries, including:
- Delivery systems and services
- Surface solutions (e.g., cosmetics, effect pigments, functional applications)
Strategic Collaborations
Merck KGaA has key partnerships with:
- Debiopharm International SA: Developing drug candidates for head and neck cancer.
- Jiangsu Hengrui Pharmaceuticals Co. Ltd.: Focused on metastatic colorectal cancer treatments.
- Abbisko Therapeutics Co. Ltd.: Targeting tenosynovial giant cell tumor therapies.
- Additional collaborations for oncogenic protein degraders.
As a subsidiary of E. Merck KGaA, the company continues to drive innovation across its diversified portfolio.
Frequently Asked Questions
-
What is Merck KGaA's (ETR-MRK) current market cap?As of 06/26/2025, Merck KGaA (including the parent company, if applicable) has an estimated market capitalization of $56.11 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Merck KGaA (ETR-MRK) rank globally by market cap?Merck KGaA global market capitalization ranking is approximately 379 as of 06/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.